Targeting the pyruvate dehydrogenase kinase/pyruvate dehydrogenase axis modulates neutrophil and smooth muscle cell pathological responses and prevents abdominal aortic aneurysm formation
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvaf032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Silke Griepke und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Renal Research Unit, Department of Molecular Medicine, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark. Hauptthemen laut MEDLINE: Aortic Aneurysm, Abdominal, Pyruvate Dehydrogenase Acetyl-Transferring Kinase, Neutrophils, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Novo Nordisk Foundation, Simon Fougner Hartmanns Familiefond, University of Southern Denmark.
Abstract (Originalsprache)
Aims
Abdominal aortic aneurysm (AAA) is a life-threatening condition where inflammation plays a key role. Currently, AAA treatment relies exclusively on surgical interventions, and no guideline drug therapy to prevent aneurysm growth or rupture is available. Pharmacological reprogramming of immune cell metabolism, through the modulation of the pyruvate dehydrogenase kinase/pyruvate dehydrogenase (PDK/PDH) axis, has been identified as an attractive strategy to combat inflammation. Here, we aimed, for the first time, to investigate the role of the PDK/PDH axis in AAA and its potential as a therapeutic target. Methods and results Analysis of three separate transcriptome data sets revealed that the expression of PDK isoenzymes is skewed in human AAA. Thus, human AAA homogenates showed increased levels of phosphorylated PDH-Ser293 and lactate compared with controls, confirming a metabolic deviation. In mice subjected to porcine pancreatic elastase (PPE)-induced AAA, treatment with dichloroacetate (DCA), a pan inhibitor of PDK isoenzymes, prevented aortic dilation, reducing the increase in inner aortic diameter by ∼58% compared with controls. Further analysis showed that DCA treatment upregulated contractile vascular smooth muscle cell (VSMC)-related genes and downregulated neutrophil-related genes in the mice. In line with the previous, PDK inhibition prevented elastin breakdown, preserved aortic alpha-smooth muscle actin and collagen expression, and decreased neutrophil infiltration and neutrophil extracellular trap (NET) release. Thus, treating VSMC with DCA or PDK1-siRNA revealed that the PDK/PDH axis regulates their dedifferentiation, influencing contractile gene expression and proliferation. Moreover, we found that DCA-induced PDK inhibition inhibited neutrophil NET release in vivo and in vitro.
Conclusion
We show that the PDK/PDH axis is skewed in human AAA. Through the inhibition of PDK, in vitro and in vivo, we demonstrated that the PDK/PDH axis is a key regulator of vascular- and neutrophil-associated pathological responses with AAA formation. Our study pinpoints immunometabolic reprogramming using PDK inhibitors as an attractive strategy to fight AAA disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular and Renal Research Unit, Department of Molecular Medicine, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark.
- Cancer and Inflammation Research Unit, Department of Molecular Medicine, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark.
- Elite Research Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Odense 5000, Denmark.
- Department of Clinical Biochemistry, Odense University Hospital, Odense 5000, Denmark.
- Unit of Genomics of Complex Diseases, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, Barcelona 17 08041, Spain.
- Center for Molecular Medicine, Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, BioClinicum, Solnavägen 30, Solna, 17 164 Stockholm, Sweden.
ORCID-Profile: Andrietta Grentzmann, Daniel F J Ketelhuth
Förderung
- Novo Nordisk Foundation
- Simon Fougner Hartmanns Familiefond
- University of Southern Denmark
- European Union's Horizon Europe Research and Innovation Framework programme for Health
- European Union
- European Health and Digital Executive Agency
- Danish Cardiovascular Academy (DCA)
- The Danish Heart Foundation
Zitieren
APA
Griepke, S., Grentzmann, A., Tripodi, G. L., Hansen, J., da Fonseca, M. P., Nilsson, M. D., Tallouzi, Y., Grupe, E., Jensen, P. S., Beck, H. C., Temprano-Sagrera, G., Sabater-Lleal, M., Burton, M., Dembic, M., Thomassen, M., Forteza, M. J., Terp, M. G., Lindholt, J. S., Rasmussen, L. M., …, & Ketelhuth, D. F. J. (2025). Targeting the pyruvate dehydrogenase kinase/pyruvate dehydrogenase axis modulates neutrophil and smooth muscle cell pathological responses and prevents abdominal aortic aneurysm formation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf032
Vancouver
Griepke S, Grentzmann A, Tripodi GL, Hansen J, da Fonseca MP, Nilsson MD, et al. Targeting the pyruvate dehydrogenase kinase/pyruvate dehydrogenase axis modulates neutrophil and smooth muscle cell pathological responses and prevents abdominal aortic aneurysm formation. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf032
BibTeX
@article{Griepke2025,
author = {Griepke, Silke and Grentzmann, Andrietta and Tripodi, Gustavo L and Hansen, Jakob and da Fonseca, Micaella Pereira and Nilsson, Michelle D and Tallouzi, Yousef and Grupe, Emilie and Jensen, Pia S and Beck, Hans C and Temprano-Sagrera, Gerard and Sabater-Lleal, Maria and Burton, Mark and Dembic, Maja and Thomassen, Mads and Forteza, Maria J and Terp, Mikkel G and Lindholt, Jes S and Rasmussen, Lars M and Steffensen, Lasse Bach and Stubbe, Jane and Ketelhuth, Daniel F J},
title = {Targeting the pyruvate dehydrogenase kinase/pyruvate dehydrogenase axis modulates neutrophil and smooth muscle cell pathological responses and prevents abdominal aortic aneurysm formation},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvaf032}
}
EUVIMED